Most people think that cancer and aging are opposites, but that is not the case. The two have more in common as both the cancerous and aging cell show genome instability which allows increased tendency of mutations to take place in the genome. In case there are mutation genes that are used to keep the DNA error-free, at times due to endogenous and exogenous factor might not be able to function properly. Thus, the DNA get vulnerable to mutation. The more the mutation accumulates, the more the cell genome becomes unstable. Thus, if more mutation accumulates, it can transform into cancer. When one age, the genome can be unstable and accumulate mutation over time. View Mikhail’s profile in LinkedIn
Endogenous and exogenous
It is this connection and the fact that it is possible to get the cure for both cancer and aging that fascinates Mikhail Blagosklonny. He is a scientist that is mainly focused on cancer and aging. He teaches at Roswell Park Cancer Institute as a professor of Oncology. Before joining Roswell, he worked at Ordway Research Institute as a senior scientist. He also worked at the New York Medical College as the assistant scientist. His research in how to deal with cancer and aging has led to the use of rapamycin medication. He has done numerous research and concluded that this is the medication that will help deal with the instability of genome. He has done intensive research on cellular, molecule, as well as clinical investigation of this drug so as to ensure that it will serve its purpose. Other than the medication, he has come up with the theory of aging hyperfunction.
Mikhail Blagosklonny got his MD and Ph.D. from the First State University. Other than his studies, he is the member of the scientific community where he works as the editor-in-chief of several publications like Cell Cycle, Aging, and Oncotarget. He has written reviews, journals, books and all these are some of the things that have made him be recognized. Most of his work is found on Oncotarget which is a journal that is open to all. The journal is gaining popularity due to the multiple peer reviews which are constructive, punctual, and insightful. This helps the authors to increase the impact of their research. The journal has known to focus on cancer and aging but has now opened doors to other researchers. Blagosklonny other than contributing to the journal is also a founder and an editor.
Read more: http://www.aging-us.com/article/100591/text